[1]	Toodayan N. Professor alois Alzheimer (1864-1915): lest we forget[J]. J Clin Neurosci, 2016, 31: 47-55. Cited in this article [1]

[2]	Association AS. 2017 Alzheimer's disease facts and figures[J]. Alzheimers Dement, 2017, 13: 325-373. Cited in this article [2]

[3]	Chan KY, Wang W, Wu JJ, et al. Epidemiology of Alzheimer's disease and other forms of dementia in China, 1990-2010: a systematic review and analysis[J]. Lancet, 2013, 381(9882): 2016-2023. Cited in this article [1]

[4]	Nichols E, Szoeke CEI, Vollset SE, et al. Global, regional, and national burden of Alzheimer's disease and other dementias, 1990-2016: a systematic analysis for the global burden of disease study 2016[J]. Lancet Neurol, 2019, 18(1): 88-106. Cited in this article [1]

[5]	Ying W, Jing Q, Rui H, et al. Alzheimer disease in China (2015-2050) estimated using the 1% population sampling survey in 2015[J]. China Journal of Alzheimer's Disease and Related Disorders, 2019, 2. Cited in this article [1]

[6]	任汝静, 殷鹏, 王志会, 等. 中国阿尔茨海默病报告2021[J]. 2021, 20(4): 21. Cited in this article [1]

[7]	Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics[J]. Sci, 2002, 297(5580): 353-356. Cited in this article [1]

[8]	Serrano-pozo A, Frosch MP, Masliah E, et al. Neuropathological alterations in Alzheimer disease[J]. Cold Spring Harb Perspect Med, 2011, 1(1): a006189. Cited in this article [1]

[9]	Fazeli E, Child DD, Bucks SA, et al. A familial missense variant in the Alzheimer's disease gene SORL1 impairs its maturation and endosomal sorting[J]. Acta Neuropathologica, 2024, 147(1): 20. Cited in this article [1]

[10]	Zhang C, Wu B, Beglopoulos V, et al. Presenilins are essential for regulating neurotransmitter release[J]. Nat, 2009, 460(7255): 632-636. Cited in this article [1]

[11]

Vetrivel KS, Barman A, Chen Y, et al. Loss of cleavage at beta'-site contributes to apparent increase in beta-amyloid peptide (Abeta) secretion by beta-secretase (BACE1)-glycosylphosphatidylinositol (GPI) processing of amyloid precursor protein[J]. J Biol Chem, 2011, 286(29): 26166-26177. Cited in this article [1]

[12]	Khanahmadi M, Farhud DD, Malmir M, et al. Genetic of Alzheimer’s disease: a narrative review article[J]. Iran J Pub Heal, 2015, 44(7): 892-901. Cited in this article [1]

[13]	Zhou L, Brouwers N, Benilova I, et al. Amyloid precursor protein mutation E682K at the alternative β-secretase cleavage β'-site increases Aβ generation[J]. EMBO Molecular Med, 2011, 3(5): 291-302. Cited in this article [1]

[14]	Sun L, Zhou R, Yang G, et al. Analysis of 138 pathogenic mutations in presenilin-1 on the in vitro production of Aβ42 and Aβ40 peptides by γ-secretase[J]. Proc National Acad Sci U S A, 2017, 114(4): E476-e485. Cited in this article [1]

[15]	Chen J, Li Q, Wang J, et al. Topsology of human apolipoprotein E3 uniquely regulates its diverse biological functions[J]. Proc Natl Acad Sci U S A, 2011, 108(36): 14813-14818. Cited in this article [1]

[16]	Reiman EM, Arboleda-Velasquez JF, Quiroz YT, et al. Exceptionally low likelihood of Alzheimer's dementia in APOE2 homozygotes from a 5,000-person neuropathological study[J]. Nat Commun, 2020, 11(1): 667. Cited in this article [2]

[17]	Yamazaki Y, Zhao N, Caulfield TR, et al. Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies[J]. Nat Review Neurol, 2019, 15(9): 501-518. Cited in this article [2]

[18]	Belloy ME, Andrews SJ, Le Guen Y, et al. APOE genotype and Alzheimer disease risk across age, sex, and population ancestry[J]. JAMA Neurol, 2023, 80(12): 1284-1294. Cited in this article [1]

[19]	Huang Y, Mahley RW. Apolipoprotein E: structure and function in lipid metabolism, neurobiology, and Alzheimer's diseases[J]. Neurobiol Dis, 2014, 72 Pt A: 3-12. Cited in this article [1]

[20]	Fortea J, Pegueroles J, Alcolea D, et al. APOE4 homozygozity represents a distinct genetic form of Alzheimer's disease[J]. Nat Med, 2024, 30(5): 1284-1291. Cited in this article [1]

[21]	Arboleda-Velasquez JF, Lopera F, O' hare M, et al. Resistance to autosomal dominant Alzheimer's disease in an APOE3 christchurch homozygote: a case report[J]. Nat Med, 2019, 25(11): 1680-1683. Cited in this article [1]

[22]	Medway CW, Abdul-hay S, Mims T, et al. ApoE variant p.V236E is associated with markedly reduced risk of Alzheimer's disease[J]. Mol Neurodegener, 2014, 9: 11. Cited in this article [1]

[23]	Le Guen Y, Belloy ME, Grenier-Boley B, et al. Association of rare APOE missense variants V236E and R251G with risk of Alzheimer disease[J]. JAMA Neurol, 2022, 79(7): 652-663. Cited in this article [1]

[24]	Guen YL, Belloy ME, Grenier‐Boley B, et al. Rare missense variant (R251G) on APOE counterbalances the Alzheimer's disease risk associated with APOE‐ε4[J]. Alzheimers Dement, 2022, 18. Cited in this article [1]

[25]	Le Guen Y, Raulin AC, Logue MW, et al. Association of african ancestry-specific apoe missense variant R145C with risk of Alzheimer disease[J]. JAMA, 2023, 329(7): 551-560. Cited in this article [1]

[26]	Kanekiyo T, Xu H, Bu G, et al. ApoE and Abeta in Alzheimer's disease: accidental encounters or partners?[J]. Neuron, 2014, 81(4): 740-754. Cited in this article [2]

[27]	Liu CC, Zhao J, Fu Y, et al. Peripheral apoE4 enhances Alzheimer's pathology and impairs cognition by compromising cerebrovascular function[J]. Nat Neurosci, 2022, 25(8): 1020-1033. Cited in this article [1]

[28]	Xu Q, Bernardo A, Walker D, et al. Profile and regulation of apolipoprotein E (ApoE) expression in the CNS in mice with targeting of green fluorescent protein gene to the ApoE locus[J]. J Neurosci, 2006, 26(19): 4985. Cited in this article [1]

[29]	Zhao N, Liu CC, Qiao W, et al. Apolipoprotein E, receptors, and modulation of Alzheimer's disease[J]. Biological psychiatry, 2017. Cited in this article [1]

[30]	Namba Y, Tomonaga M, Kawasaki H, et al. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in creutzfeldt-jakob disease[J]. Brain Research, 1991, 541,(1): 163-166. Cited in this article [1]

[31]	Huang YA, Zhou B, Wernig M, et al. ApoE2, ApoE3, and ApoE4 differentially stimulate APP transcription and Aβ secretion[J]. Cell, 2017, 168(3): 427. Cited in this article [3]

[32]	Christensen DZ, Schneideraxmann T, Lucassen PJ, et al. Accumulation of intraneuronal Aβ correlates with ApoE4 genotype[J]. Acta Neuropathologica, 2010, 119(5): 555-566. Cited in this article [1]

[33]	Hashimoto T, Serranopozo A, Hori Y, et al. Apolipoprotein E, especially apolipoprotein E4, increases the oligomerization of amyloid β peptide[J]. J Neurosci, 2012, 32(43): 15181. Cited in this article [1]

[34]	Yu JT, Tan L, Hardy J, et al. Apolipoprotein E in Alzheimer's disease: an update[J]. Annu Rev Neurosci, 2014, 37: 79-100. Cited in this article [1]

[35]	Cerf E, Gustot A, Goormaghtigh E, et al. High ability of apolipoprotein E4 to stabilize amyloid-β peptide oligomers, the pathological entities responsible for Alzheimer's disease[J]. FASEB J, 2011, 25(5): 1585. Cited in this article [1]

[36]	Liu CC, Zhao N, Fu Y, et al. ApoE4 accelerates early seeding of amyloid pathology[J]. Neuron, 2017, 96(5): 1024-1032 e3. Cited in this article [2]

[37]	Huynh TV, Liao F, Francis CM, et al. Age-dependent effects of apoe reduction using antisense oligonucleotides in a model of beta-amyloidosis[J]. Neuron, 2017, 96(5): 1013-1023 e4. Cited in this article [2]

[38]	Lin YT, Seo J, Gao F, et al. APOE4 causes widespread molecular and cellular alterations associated with Alzheimer's disease phenotypes in human iPSC-derived brain cell types[J]. Neuron, 2018, 98(6): 1141-1154.e7. Cited in this article [3]

[39]	Xiong M, Wang C, Gratuze M, et al. Astrocytic APOE4 removal confers cerebrovascular protection despite increased cerebral amyloid angiopathy[J]. Mol Neurodegener, 2023, 18(1): 17. Cited in this article [2]

[40]	Shi Y, Yamada K, Liddelow SA, et al. ApoE4 markedly exacerbates Tau-mediated neurodegeneration in a mouse model of tauopathy[J]. Nature, 2017, 549(7673): 523-527. Cited in this article [4]

[41]	Martens YA, Zhao N, Liu CC, et al. ApoE cascade hypothesis in the pathogenesis of Alzheimer's disease and related dementias[J]. Neuron, 2022, 110(8): 1304-1317. Cited in this article [1]

[42]	Koutsodendris N, Blumenfeld J, Agrawal A, et al. Neuronal APOE4 removal protects against tau-mediated gliosis, neurodegeneration and myelin deficits[J]. Nat Aging, 2023, 3(3): 275-296. Cited in this article [2]

[43]	Knoferle J, Yoon SY, Walker D, et al. Apolipoprotein E4 produced in GABAergic interneurons causes learning and memory deficits in mice[J]. J Neurosci, 2014, 34(42): 14069-14078. Cited in this article [1]

[44]	Xu Q, Bernardo A, Walker D, et al. Profile and regulation of apolipoprotein E (ApoE) expression in the CNS in mice with targeting of green fluorescent protein gene to the ApoE locus[J]. J Neurosci, 2006, 26(19): 4985-4994. Cited in this article [1]

[45]	Zalocusky KA, Najm R, Taubes AL, et al. Neuronal ApoE upregulates MHC-I expression to drive selective neurodegeneration in Alzheimer's disease[J]. Nat Neurosci, 2021, 24(6): 786-798. Cited in this article [5]

[46]	Han SH, Hulette C, Saunders AM, et al. Apolipoprotein E is present in hippocampal neurons without neurofibrillary tangles in Alzheimer's disease and in age-matched controls[J]. Experim Neurol, 1994, 128(1): 13. Cited in this article [1]

[47]	Strittmatter WJ Saunders AM, Schmechel D, et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease[J]. Proc Nat Acad Sci U S A, 1993, 90(5):1977-1981. Cited in this article [1]

[48]	Metzger RE, Ladu MJ, Pan JB, et al. Neurons of the human frontal cortex display apolipoprotein E immunoreactivity: implications for Alzheimer's disease[J]. J Neuropathol Experiment Neurol, 1996, 55(3): 372-380. Cited in this article [2]

[49]	Zarow C, Victoroff J. Increased apolipoprotein E mRNA in the hippocampus in Alzheimer disease and in rats after entorhinal cortex lesioning[J]. Experiment Neurol, 1998, 149(1): 79-86. Cited in this article [2]

[50]	Xu PT, Gilbert JR, Qiu HL, et al. Specific regional transcription of apolipoprotein E in human brain neurons[J]. A J Path, 1999, 154(2): 601-611. Cited in this article [2]

[51]	Aoki K, Uchihara T, Nakamura A, et al. Expression of apolipoprotein E in ballooned neurons-comparative immunohistochemical study on neurodegenerative disorders and infarction[J]. Acta Neuropathol, 2003, 106(5): 436-440. Cited in this article [1]

[52]	Brecht WJ, Harris FM, Chang S, et al. Neuron-specific apolipoprotein e4 proteolysis is associated with increased Tau phosphorylation in brains of transgenic mice[J]. J Neurosci, 2004, 24(10): 2527-2534. Cited in this article [1]

[53]	Belonwu SA, Li Y, Bunis D, et al. Sex-stratified single-cell RNA-seq analysis identifies sex-specific and cell type-specific transcriptional responses in Alzheimer's disease across two brain regions[J]. Mol Neurobiol, 2022, 59(1): 276-293. Cited in this article [1]

[54]	Hou X, Zhang X, Zou H, et al. Differential and substrate-specific inhibition of γ-secretase by the C-terminal region of ApoE2, ApoE3, and ApoE4[J]. Neuron, 2023, 111(12): 1898-1913.e5. Cited in this article [11]

[55]	Strittmatter WJ, Saunders AM, Schmechel D, et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease[J]. Proc Nati Acad Sci U S A, 1993, 90(5): 1977-1981. Cited in this article [1]

[56]	Xia Y, Wang ZH, Zhang J, et al. C/EBPβ is a key transcription factor for APOE and preferentially mediates ApoE4 expression in Alzheimer's disease[J]. Mol Psychiatry, 2021, 26(10): 6002-6022. Cited in this article [1]

[57]	Xu Q, Walker D, Bernardo A, et al. Intron-3 retention/splicing controls neuronal expression of apolipoprotein E in the CNS[J]. J Neurosci, 2008, 28(6): 1452-1459. Cited in this article [1]

[58]	Blumenfeld J, Yip O, Kim MJ, et al. Cell type-specific roles of APOE4 in Alzheimer disease[J]. Nat Rev Neurosci, 2024, 25(2): 91-110. Cited in this article [9]

[59]	Wang C, Najm R, Xu Q, et al. Gain of toxic apolipoprotein E4 effects in human iPSC-derived neurons is ameliorated by a small-molecule structure corrector[J]. Nat Med, 2018, 24(5): 647-657. Cited in this article [6]

[60]	Jackson RJ, Hyman BT, Serrano-Pozo A, et al. Multifaceted roles of APOE in Alzheimer disease[J]. Nat Rev Neurol, 2024, 20(8):457-474. Cited in this article [7]

[61]	Narasimhan S, Holtzman DM, Apostolova LG, et al. Apolipoprotein E in Alzheimer's disease trajectories and the next-generation clinical care pathway[J]. Nat Neurosci, 2024, 27(7):1236-1252. Cited in this article [3]

[62]	Wadhwani AR, Affaneh A, Van Gulden S, et al. Neuronal apolipoprotein E4 increases cell death and phosphorylated tau release in Alzheimer disease[J]. Ann Neurol, 2019, 85(5): 726-739. Cited in this article [2]

[63]	Wang ZH, Xia Y, Wu Z, et al. Neuronal ApoE4 stimulates C/EBPβ activation, promoting Alzheimer's disease pathology in a mouse model[J]. Prog Neurobiol, 2022, 209: 102212. Cited in this article [1]

[64]	Serrano-Pozo A, Das S, Hyman BT, et al. APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therapeutic approaches[J]. Lancet Neurol, 2021, 20(1): 68-80. Cited in this article [1]

[65]	Pankiewicz JE, Guridi M, Kim J, et al. Blocking the apoE/Aβ interaction ameliorates Aβ-related pathology in APOE ε2 and ε4 targeted replacement Alzheimer model mice[J]. Acta Neuropathologica Communications, 2014, 2: 75. Cited in this article [1]

[66]	Liao F, Hori Y, Hudry E, et al. Anti-ApoE antibody given after plaque onset decreases Aβ accumulation and improves brain function in a mouse model of Aβ amyloidosis[J]. J Neurosci, 2014, 34(21): 7281-7292. Cited in this article [1]

[67]	Liao F, Li A, Xiong M, et al. Targeting of nonlipidated, aggregated apoE with antibodies inhibits amyloid accumulation[J]. J Clin Invest, 2018, 128(5): 2144-2155. Cited in this article [1]

[68]	Krishnamurthy K, Cantillana V, Wang H, et al. ApoE mimetic improves pathology and memory in a model of Alzheimer's disease[J]. Brain Res, 2020, 1733: 146685. Cited in this article [1]

[69]	Vitek MP, Christensen DJ, Wilcock D, et al. APOE-mimetic peptides reduce behavioral deficits, plaques and tangles in Alzheimer's disease transgenics[J]. Neuro-degener Dis, 2012, 10(1-4): 122-126. Cited in this article [1]

[70]	Ghosal K, Stathopoulos A, Thomas D, et al. The apolipoprotein-E-mimetic COG112 protects amyloid precursor protein intracellular domain-overexpressing animals from Alzheimer's disease-like pathological features[J]. Neurodegener Dis, 2013, 12(1): 51-58. Cited in this article [1]

[71]	Zhao L, Gottesdiener AJ, Parmar M, et al. Intracerebral adeno-associated virus gene delivery of apolipoprotein E2 markedly reduces brain amyloid pathology in Alzheimer's disease mouse models[J]. Neurobiol Aging, 2016, 44: 159-172. Cited in this article [1]

[72]	Rosenberg JB, Kaplitt MG, De BP, et al. AAVrh.10-Mediated APOE2 central nervous system gene therapy for APOE4-associated Alzheimer's disease[J]. Hum Gene Ther Clin Dev, 2018, 29(1): 24-47. Cited in this article [1]

[73]	Litvinchuk A, Huynh TV, Shi Y, et al. Apolipoprotein E4 reduction with antisense oligonucleotides decreases neurodegeneration in a tauopathy model[J]. Ann Neurol, 2021, 89(5): 952-966. Cited in this article [1]

[74]	Sevigny J, Chiao P, BussiÈre T, et al. The antibody aducanumab reduces Aβ plaques in Alzheimer's disease[J]. Nature, 2016, 537(7618): 50-56. Cited in this article [1]

[75]	Wang D, Tai PWL, Gao G, et al. Adeno-associated virus vector as a platform for gene therapy delivery[J]. Nat Rev Drug Discov, 2019, 18(5): 358-378. Cited in this article [3]

[76]	Raguram A, Banskota S, Liu DR, et al. Therapeutic in vivo delivery of gene editing agents[J]. Cell, 2022, 185(15): 2806-2827. Cited in this article [1]

[77]	Gomez Limia C, Baird M, Schwartz M, et al. Emerging perspectives on gene therapy delivery for neurodegenerative and neuromuscular disorders[J]. J Pers Med, 2022, 12(12). Cited in this article [1]